Press Releases

Date Title and Summary    
Toggle Summary Rexahn Files Patent Application for Quinazoline-Based Anti-Cancer Drug Candidate
Rockville, MD, February 19, 2004 – Rexahn, an emerging, privately-held biopharmaceutical company focusing on the development of first-in-class signal inhibitor therapeutics, announced today that it has submitted a provisional patent application for its Quinazoline-based anti-cancer drug candidates.
View HTML Print
Toggle Summary Rexahn Receives $100,000 Technology Growth Program Grant from Montgomery County
Rockville, MD, January 9, 2004 – Rexahn Corporation announced today that that it has received the prestigious $100,000 as a Technology Growth Program (TGP) Grant from Department of Economic development of Montgomery County, Maryland. TGP was created in 1999 to stimulate and facilitate growth and
View HTML Print
Toggle Summary Rexahn Completes $2,000,000 Private Placement from KT&G Corporation
Rockville, MD, August 7, 2003 – Rexahn Corp. announced today that that it has raised a $2,000,000 through the sale in a private placement of 500,000 shares of common stock to KT&G Corporation. Furthermore, through the MOU on June 24, 2003, KT&G will consider supporting the research and development
View HTML Print
Toggle Summary Rexahn Announces Crada Agreement with The National Cancer Institute
Rockville, MD, May 6, 2003 – Rexahn Corp. announced today that it has signed a Collaborative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) at the National Institutes of Health. The agreement provides for NCI and Rexahn to investigate the effect of a family of
View HTML Print
Toggle Summary Rexahn Announces Joint Research Agreement with The KRICT
Rockville, MD, March 20, 2003 – Rexahn Corp. announced today that it has entered into a joint research agreement with the Korea Research Institute of Chemical Technology (KRICT), a quasi-government research institute in Korea. The purpose of this collaboration is to accelerate the discovery of
View HTML Print
Toggle Summary Rexahn Announces Filing of a Patent Application for a Novel Anti-Cancer
Rockville, MD, March 20, 2003 – Rexahn Corp. announced today that it has submitted a patent application for its recently discovered anti-cancer drug, RX-0047. The new drug candidate inhibits expression of HIF-1, a human protein that leads to rapid cancer growth.
View HTML Print
Toggle Summary Rexahn Announces License Agreement with Rexgene
Rockville, MD, March 18, 2003 – Rexahn Corp. announced today that it has signed a Research Collaboration Agreement with Rexgene Biotech Co. Ltd, a Korean biotech company headquartered in Seoul, Korea. The agreement provides for the companies to develop a research and development plan for the
View HTML Print


©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy